1. Home
  2. COMP vs GKOS Comparison

COMP vs GKOS Comparison

Compare COMP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Inc.

COMP

Compass Inc.

HOLD

Current Price

$10.67

Market Cap

4.9B

Sector

Technology

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$115.02

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COMP
GKOS
Founded
2012
1998
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.4B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
COMP
GKOS
Price
$10.67
$115.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
13
Target Price
$10.83
$126.38
AVG Volume (30 Days)
9.7M
697.5K
Earning Date
02-17-2026
02-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,642,200,000.00
$469,820,000.00
Revenue This Year
$25.14
$31.15
Revenue Next Year
$12.29
$24.15
P/E Ratio
N/A
N/A
Revenue Growth
24.27
30.38
52 Week Low
$5.10
$73.16
52 Week High
$11.07
$163.71

Technical Indicators

Market Signals
Indicator
COMP
GKOS
Relative Strength Index (RSI) 56.66 67.78
Support Level $10.44 $115.07
Resistance Level $10.79 $117.94
Average True Range (ATR) 0.36 2.73
MACD -0.08 -0.46
Stochastic Oscillator 53.48 72.50

Price Performance

Historical Comparison
COMP
GKOS

About COMP Compass Inc.

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: